ROIV

Roivant Sciences
D

ROIV

Arincen25/100B

Roivant Sciences cash flow statement 2019–2026

In fiscal year 2025 Roivant Sciences spent 319.50M USD buying back its shares and paid 0.00 USD in dividends: 319.50M USD in all.

Operating cash flow Free cash flow

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Mar 2026
FY2024
31 Mar 2025
FY2023
31 Mar 2024
FY2022
31 Mar 2023
FY2021
31 Mar 2022
FY2020
31 Mar 2021
FY2019
31 Mar 2020
Net income
-385.77M-397.91M-356.73M4.23B-1.12B-924.12M-900.23M-519.39M
Depreciation and amortization
2.53M3.35M14.07M22.04M18.86M5.93M0.000.00
Stock-based compensation
344.81M346.17M289.03M199.63M217.78M564.96M84.96M0.00
Change in working capital
—-621.80M-77.05M19.04M6.35M15.72M71.94M15.30M
Change in receivables
—-770.24M0.000.000.000.000.000.00
Change in inventory
—0.000.000.000.000.000.000.00
Change in payables
5.62M3.42M-18.17M22.68M4.36M15.40M3.75M6.60M
Change in other working capital
—145.02M-58.88M-3.65M1.99M316.00K68.19M8.70M
Other non-cash items
593.75M-80.16M-708.77M-5.24B29.09M-340.22M191.20M-257.73M
Operating cash flow
-29.28M-750.35M-839.45M-765.27M-843.39M-677.73M-552.14M-761.83M
Capital expenditure
—-8.21M-4.60M-1.38M-12.69M-17.44M-5.81M-4.92M
Acquisitions
—0.00229.36M-36.98M107.86M-39.00K0.001.77B
Purchases of investments
—0.00-4.06B0.000.000.000.00-68.38M
Sales and maturities of investments
-1.87B-37.49M1.96B0.000.00320.17M0.0016.44M
Other investing
-301.60M-636.64M110.47M5.24B-139.43M600.00K-25.90M-20.05M
Investing cash flow
606.76M-682.33M-1.77B5.20B-44.27M303.30M-31.70M1.69B
Debt issued (repaid)
—0.00-52.75M-30.71M129.76M14.81M0.00-32.06M
Shares issued
—463.11M112.78M438.56M379.71M100.41M455.76M1.35B
Share buybacks
—-319.50M-1.29B0.000.000.000.00-1.19B
Dividends paid
—0.000.00-6.00M0.000.000.000.00
Other financing
-424.08M-9.37M13.41M17.51M-10.00M191.57M508.00K83.48M
Financing cash flow
-378.04M134.24M-1.22B419.36M499.46M306.79M456.26M217.16M
Net change in cash
—-1.29B-3.82B4.86B-381.92M-68.44M-127.58M1.34B
Free cash flow
—-758.56M-844.05M-766.65M-856.08M-695.17M-557.94M-766.75M
Free cash flow margin
—-9,183.51%-2,905.21%-2,343.56%-2,715.14%-1,257.40%-2,344.80%-1,132.75%
Free cash flow per share
—-1.09-1.16-0.92-1.20-1.04-0.81-1.12
Interest paid
——5.96M10.27M5.30M5.54M2.02M—
Income taxes paid
—0.0061.91M12.35M5.13M916.00K4.08M0.00

Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Common questions about Roivant Sciences's cash flow

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.